

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 July 2025 (24.07.2025)



(10) International Publication Number
WO 2025/153532 A1

(51) International Patent Classification:

A61K 31/506 (2006.01) *A61P 3/04* (2006.01)
A61K 31/5395 (2006.01) *A61P 3/06* (2006.01)
A61K 31/64 (2006.01) *A61P 3/10* (2006.01)
A61K 45/06 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

(21) International Application Number:

PCT/EP2025/050888

(22) International Filing Date:

15 January 2025 (15.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(30) Priority Data:

63/621,412 16 January 2024 (16.01.2024) US

(71) Applicant: **NODTHERA LIMITED** [GB/GB]; Suite 8, The Mansion, Chesterford Research Park, Little Chesterford CB10 1XL (GB).

(72) Inventors: **WATT, Alan Paul**; c/o NodThera Limited, Suite 8, The Mansion, Chesterford Research Park, Little Chesterford CB10 1XL (GB). **CLARKE, Nicholas**; c/o NodThera Limited, Suite 8, The Mansion, Chesterford Research Park, Little Chesterford CB10 1XL (GB). **THORNTON, Peter**; c/o NodThera Limited, Suite 8, The Mansion, Chesterford Research Park, Little Chesterford CB10 1XL (GB).

(74) Agent: **GIBSON, Mark**; Sagittarius IP, Marlow International Parkway, Marlow SL7 1YL (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: NLRP3 INHIBITORS AND GLP-1 AGONISTS COMBINATION THERAPIES

(57) Abstract: Provided herein are combinations of NLRP3 inflammasome inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists and methods comprising administering to a subject in need thereof such combinations for the treatment of a GLP-1 linked disease and/or a weight disorder.

WO 2025/153532 A1